ATX-GD-59 (1.6mg)
$82.50
This product is supplied for laboratory research use only and is not intended for human use. Lyophilized products may require appropriate laboratory reconstitution and handling.
Description
Introducing ATX-GD-59, a cutting-edge peptide-based therapy meticulously crafted for the management of Graves’ disease. With a molecular weight of 2529.26 and a molecular formula of C114H198N32O32, ATX-GD-59 surpasses research-grade benchmarks, highlighting our unwavering dedication to excellence and pioneering advancements.
ATX-GD-59 redefines medical paradigms through its innovative mode of action, engineered to emulate epitopes and effectively immobilize the leukocytes responsible for assaulting the thyroid. It obstructs the generation of anti-thyroid stimulating hormone receptor (TSHR) stimulatory antibodies, revolutionizing the approach beyond conventional treatments. This advanced strategy homes in on the immunological foundation of Graves’ disease, marking a transformative path in disease management brought forth by ATX-GD-59.
Additional Information
Benefits
Please review the complete product description and available supporting documentation for product-specific research information. This product is sold strictly for laboratory research use.
Mechanism of Action
Refer to the product description, certificate of analysis and applicable published research for product-specific information. No medical or therapeutic claims are made.
